Blaine Templeman has joined the New York office of Sheppard, Mullin, Richter, & Hampton as a partner in the firm’s intellectual property practice group.
Templeman will head Sheppard Mullin’s new biotech clinical contracting team. He joins Sheppard Mullin from the New York office of Heller Ehrman, where he was a partner.
Templeman received a JD from the New York University School of Law and a BA from Oral Roberts University.
Introgen said this week that it has appointed James Rothman to its board of directors.
Rothman, who is currently professor of chemical biology at Columbia University, will relocate his laboratory in September to Yale University where he will serve as professor of biomedical sciences, chairman of the department of cell biology, and founder of the Yale University Center for High-Throughput Cell Biology.
Prior to his work at Columbia, Rothman served as vice chairman of the Sloan-Kettering Research Institute of Memorial Sloan-Kettering Cancer Center. He has also served as chief scientist at GE Healthcare, and is currently the senior scientific advisor for biomedical research at GE's Global Research Center. Rothman has also previously served on scientific advisory boards of Johnson & Johnson, GlaxoSmithKline, Amersham, Ariad Pharmaceuticals, and Merck, and currently advises Eli Lilly in oncology.
The American Intellectual Property Law Association announced last week that Todd Dickinson will serve as its new executive director.
Dickinson joins the AIPLA following an announcement by current executive director Mike Kirk that he will officially step down from the position on Aug. 31. Dickinson previously served as vice president and chief intellectual property counsel for GE. He also served as under secretary of commerce for intellectual property and director of the US Patent and Trademark Office from 1999 to 2001. After leaving the USPTO, he became a partner in the law firm of Howrey LLP, where he led the intellectual property practice.
Dickinson holds a JD from the University of Pittsburgh School of Law.
Kelvin Lee has been appointed the new director of the Delaware Biotechnology Institute, DBI said last week.
Lee is currently professor of chemical engineering and DBI faculty fellow at the University of Delaware. He joined the UD faculty in 2007 from Cornell University, where he served as professor of molecular and cell biology, professor of chemical and biomeolecular engineering, and director of the Institute for Biotechnology and Life Science Technologies. He holds a PhD and MS from the California Institute of Technology.
Lee replaces David Weir, who had directed DBI since its inception in 1998 until this year, when he was named director of the University of Delaware’s Office of Economic Innovation and Partnerships.